Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 66
Selected: 0
NCT IDTitle
NCT06617000A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related
NCT03488160CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma
NCT05472610Study of Efficacy of BZ019 in Large B-cell Lymphoma
NCT04067414Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma
NCT06005649Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
NCT04690192CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma
NCT05667506A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
NCT05373147αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors
NCT06505551Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma
NCT06732232A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
NCT02729493Study Evaluating the Efficacy and Safety With CAR-T for Liver Cancer
NCT02975687CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia
NCT06446128A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)
NCT06826430Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia
NCT04028440γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
NCT04232826A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma
NCT03029338CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma
NCT06327997An Exploratory Study by Fast CAR T Cells
NCT04684147Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT02919046Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children
NCT04489862αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors
NCT06608732Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
NCT01621724WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study
NCT06212388Allogeneic Gammadelta T Cells Combined With Interferon-α1b or PD-1 Monoclonal Antibody in Stage III-IV Amenable to Surgical Resection Melanoma
NCT05984550The Exploratory Study on the Nicotinamide Mononucleotide (Vital NAD ) to Promote the Rejuvenation of the Peripheral Blood Immune Cells of Adults.
NCT06316791Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases
NCT05872659Mesenchymal Stem Cells for Immune Non-responder Patients With HIV Infection
NCT06036355The Exploratory Study on the Biological Function of Dendritic Cells In Vivo Supported by Nicotinamide Mononucleotide (Vital NAD)
NCT06676982Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma
NCT04008524A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies
NCT06231368CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.
NCT05417932A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma
NCT04518774Allogeneic "Gammadelta T Cells (γδ T Cells)" Cell Immunotherapy in Phase 1 Hepatocellular Carcinoma Clinical Trial
NCT02735291Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia
NCT06364787Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma
NCT06009107A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)
NCT06450067Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
NCT05944185Phase I/II Study of αPD1-MSLN-CAR T Cells in MSLN-positive Advanced Solid Tumors
NCT06461351Long-term Observational Study of Patients Treated With Inaticabtagene Autoleucel Injection
NCT04696705Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients
NCT05997628The Exploratory Study on the Baseline Level of NAD+/NADH in Peripheral Blood Samples of Different Gender and Age Groups of Healthy Adults.
NCT04034446CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)
NCT06249256An Exploratory Study on the Treatment of Advanced Solid Tumors by Fast CAR T Cells
NCT07146672Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors
NCT06364800Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody
NCT07048353CD30 CAR-T in the Treatment of CD30 Positive Lymphoma
NCT02725125Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer
NCT05089266Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors
NCT06015269Exploratory Study on Baize DC Injection in Preventing Recurrence and Metastasis After Radical Tumor Surgery
NCT04586478Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma